{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:48:26Z","timestamp":1784566106587,"version":"3.55.0"},"reference-count":52,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15347","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:19:11Z","timestamp":1760703551000},"page":"1-9","source":"Crossref","is-referenced-by-count":1,"title":["Gamma Knife consolidation therapy improves prognosis in patients with advanced epidermal growth factor receptor\u2011mutant lung adenocarcinoma treated with first\u2011generation epidermal growth factor receptor\u2011tyrosine kinase inhibitors"],"prefix":"10.3892","volume":"30","author":[{"given":"Bin","family":"Xu","sequence":"first","affiliation":[{"name":"People's Liberation Army Clinical College, Anhui Medical University, Hefei, Anhui 230031, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghui","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, 901st Hospital of The Joint Logistics Support Force of The People's Liberation Army, Hefei, Anhui 230031, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, 901st Hospital of The Joint Logistics Support Force of The People's Liberation Army, Hefei, Anhui 230031, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, 901st Hospital of The Joint Logistics Support Force of The People's Liberation Army, Hefei, Anhui 230031, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, 901st Hospital of The Joint Logistics Support Force of The People's Liberation Army, Hefei, Anhui 230031, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, 901st Hospital of The Joint Logistics Support Force of The People's Liberation Army, Hefei, Anhui 230031, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, 901st Hospital of The Joint Logistics Support Force of The People's Liberation Army, Hefei, Anhui 230031, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglai","family":"Lv","sequence":"additional","affiliation":[{"name":"People's Liberation Army Clinical College, Anhui Medical University, Hefei, Anhui 230031, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"key20251111104023_b1-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"key20251111104023_b2-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"key20251111104023_b3-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"key20251111104023_b4-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"key20251111104023_b5-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2147\/OTT.S98363","article-title":"Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer","volume":"9","author":"Shen","year":"2016","journal-title":"Onco Targets Ther"},{"key":"key20251111104023_b6-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/annonc\/mds529","article-title":"Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: A phase II study (CTONG-0803)","volume":"24","author":"Wu","year":"2013","journal-title":"Ann Oncol"},{"key":"key20251111104023_b7-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.lungcan.2013.08.016","article-title":"Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma","volume":"82","author":"Iuchi","year":"2013","journal-title":"Lung Cancer"},{"key":"key20251111104023_b8-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.xcrm.2020.100007","article-title":"Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer","volume":"1","author":"Roper","year":"2020","journal-title":"Cell Rep Med"},{"key":"key20251111104023_b9-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1001\/jamaoncol.2015.4921","article-title":"First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in asian patients with epidermal growth factor receptor Mutation-positive Non-Small-Cell lung cancer: The ASPIRATION study","volume":"2","author":"Park","year":"2016","journal-title":"JAMA Oncol"},{"key":"key20251111104023_b10-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-11-1468","article-title":"Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design","volume":"17","author":"Chaft","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20251111104023_b11-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"113","DOI":"10.21037\/jtd.2017.12.77","article-title":"Perspectives on oligometastasis: Challenges and opportunities","volume":"10","author":"Heitmann","year":"2018","journal-title":"J Thorac Dis"},{"key":"key20251111104023_b12-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/j.cllc.2018.09.010","article-title":"Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations","volume":"20","author":"Hu","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"key20251111104023_b13-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"491","DOI":"10.21037\/tlcr-23-830","article-title":"Additional local therapy before disease progression for EGFR-mutated advanced lung cancer: A systematic review and meta-analysis","volume":"13","author":"Seong","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"key20251111104023_b14-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ijrobp.2006.04.013","article-title":"Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I\/II non-small-cell lung cancer","volume":"66","author":"Xia","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20251111104023_b15-ol-30-6-15347","first-page":"1204","article-title":"Efficacy of whole body gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer","volume":"27","author":"Zhang","year":"2008","journal-title":"Chin J Cancer"},{"key":"key20251111104023_b16-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3892\/ijo.2014.2295","article-title":"Stereotactic radiosurgery, a potential alternative treatment for pulmonary metastases from osteosarcoma","volume":"44","author":"Yu","year":"2014","journal-title":"Int J Oncol"},{"key":"key20251111104023_b17-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"e0187350","DOI":"10.1371\/journal.pone.0187350","article-title":"Local thoracic therapy improve prognosis for stage IV non-small cell lung cancer patients combined with chemotherapy: A Surveillance, Epidemiology, and End Results database analysis","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS One"},{"key":"key20251111104023_b18-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic Non-Small-Cell lung cancer: Long-Term results of a Multi-Institutional, Phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20251111104023_b19-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20251111104023_b20-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of First-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-Mutated Non-Small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"key20251111104023_b21-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1245\/s10434-022-11483-7","article-title":"Primary tumor resection for Stage IV Non-small-cell lung cancer without progression After First-Line epidermal growth factor receptor-tyrosine kinase inhibitor treatment: A retrospective Case-Control study","volume":"29","author":"Kuo","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"key20251111104023_b22-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.2147\/OTT.S300267","article-title":"Primary tumor radiotherapy during EGFR-TKI disease control improves survival of treatment na\u00efve advanced EGFR-Mutant lung adenocarcinoma patients","volume":"14","author":"Hsu","year":"2021","journal-title":"Onco Targets Ther"},{"key":"key20251111104023_b23-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"109681","DOI":"10.1016\/j.radonc.2023.109681","article-title":"EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study","volume":"184","author":"Peng","year":"2023","journal-title":"Radiother Oncol"},{"key":"key20251111104023_b24-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.jtho.2018.05.019","article-title":"Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR Activating mutation treated with first-line EGFR-TKIs","volume":"13","author":"Xu","year":"2018","journal-title":"J Thorac Oncol"},{"key":"key20251111104023_b25-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12094-017-1723-1","article-title":"Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment","volume":"20","author":"Wang","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"key20251111104023_b26-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3171\/2021.9.JNS211373","article-title":"Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with brain metastases","volume":"137","author":"Chiou","year":"2021","journal-title":"J Neurosurg"},{"key":"key20251111104023_b27-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"17588359231220606","DOI":"10.1177\/17588359231220606","article-title":"Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib","volume":"16","author":"Wu","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"key20251111104023_b28-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijrobp.2019.12.042","article-title":"Pattern of Recurrence analysis in metastatic EGFR-Mutant NSCLC treated with osimertinib: Implications for consolidative stereotactic body radiation therapy","volume":"107","author":"Guo","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20251111104023_b29-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20251111104023_b30-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1054\/bjoc.2001.2162","article-title":"Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer","volume":"85","author":"Ando","year":"2001","journal-title":"Br J Cancer"},{"key":"key20251111104023_b31-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"NCCN guidelines insights: Non-Small cell lung cancer, version 2022","volume":"20","author":"Ettinger","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"key20251111104023_b32-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"key20251111104023_b33-ol-30-6-15347","first-page":"34","article-title":"4D-CT-based plan target volume (PTV) definition compared with conventional PTV definition using general margin in radiotherapy for lung cancer","volume":"36","author":"Ju","year":"2014","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"key20251111104023_b34-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the radiation therapy oncology group (RTOG) and the european organization for research and treatment of cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20251111104023_b35-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"1028132","DOI":"10.3389\/fonc.2022.1028132","article-title":"Local therapy treatment conditions for oligometastatic non-small cell lung cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"key20251111104023_b36-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic Non-Small-Cell lung cancer: A Phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"key20251111104023_b37-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2020.12.037","article-title":"Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment","volume":"153","author":"Ohtaki","year":"2021","journal-title":"Lung Cancer"},{"key":"key20251111104023_b38-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000509664","article-title":"Primary tumor resection is associated with a better outcome among advanced EGFR-Mutant lung adenocarcinoma patients receiving EGFR-TKI treatment","volume":"99","author":"Tseng","year":"2021","journal-title":"Oncology"},{"key":"key20251111104023_b39-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s00595-024-02811-3","article-title":"Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor\/immune checkpoint inhibitor before salvage surgery","volume":"54","author":"Takenaka","year":"2024","journal-title":"Surg Today"},{"key":"key20251111104023_b40-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cllc.2018.09.015","article-title":"Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic Non-small-cell lung cancer (NSCLC)","volume":"20","author":"Elamin","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"key20251111104023_b41-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s00066-022-01971-w","article-title":"Primary lesion radiotherapy during first-line icotinib treatment in EGFR-mutated NSCLC patients with multiple metastases and no brain metastases: A single-center retrospective study","volume":"198","author":"Deng","year":"2022","journal-title":"Strahlenther Onkol"},{"key":"key20251111104023_b42-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ygyno.2012.02.024","article-title":"Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: Redefining \u2018optimal\u2019 residual disease","volume":"125","author":"Chang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"key20251111104023_b43-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","article-title":"Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial","volume":"30","author":"Koole","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"key20251111104023_b44-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.athoracsur.2023.01.027","article-title":"Salvage surgery for advanced lung adenocarcinoma after epidermal growth factor receptor tyrosine kinase inhibitor treatment","volume":"116","author":"Lin","year":"2023","journal-title":"Ann Thorac Surg"},{"key":"key20251111104023_b45-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1097\/JTO.0000000000000648","article-title":"Pattern of failure analysis in metastatic EGFR-Mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy","volume":"10","author":"Al-Halabi","year":"2015","journal-title":"J Thorac Oncol"},{"key":"key20251111104023_b46-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"key20251111104023_b47-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/jpm11010053","article-title":"Radiation response in the tumour microenvironment: Predictive biomarkers and future perspectives","volume":"11","author":"Byrne","year":"2021","journal-title":"J Pers Med"},{"key":"key20251111104023_b48-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1136\/jclinpath-2011-200169","article-title":"Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations","volume":"64","author":"Won","year":"2011","journal-title":"J Clin Pathol"},{"key":"key20251111104023_b49-ol-30-6-15347","first-page":"3887","article-title":"Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer","volume":"18","author":"Hong","year":"2019","journal-title":"Oncol Lett"},{"key":"key20251111104023_b50-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11523-020-00724-y","article-title":"Clinical factors affecting the response to osimertinib in Non-Small cell lung cancer patients with an acquired epidermal growth factor receptor T790M mutation: A Long-Term survival analysis","volume":"15","author":"Chen","year":"2020","journal-title":"Target Oncol"},{"key":"key20251111104023_b51-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-Mutated advanced Non-Small-Cell Lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"key20251111104023_b52-ol-30-6-15347","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:40:27Z","timestamp":1762850427000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,10,17]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15347","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}